A Clinical Trial of Antiplatelets in Psoriasis

The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.

NCT Number	NCT07744191
Lead Sponsor	NYU Langone Health Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Psoriasis (PsO), Psoriatic Arthritis (PsA)
Enrollment	60 participants
Start Date	2026-09
Primary Completion	2031-09 (estimated)
Study Completion	2031-09 (estimated)
Updated on ClinicalTrials.gov	2026-08-05